Literature DB >> 2314120

AcSDKP, an inhibitor of CFU-S proliferation, is synthesized in mice under steady-state conditions and secreted by bone marrow in long-term culture.

J Wdzieczak-Bakala1, M P Fache, M Lenfant, E Frindel, F Sainteny.   

Abstract

The peptide AcSDKP, isolated from fetal calf bone marrow, is able to prevent DNA synthesis in mouse CFU-S in vivo and in vitro. The molecule is demonstrated here to be constitutively produced in mice and synthesized by bone marrow cells in long term culture.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2314120

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  9 in total

1.  Effect of N-acetyl-seryl-aspartyl-lysyl-proline on DNA and collagen synthesis in rat cardiac fibroblasts.

Authors:  N E Rhaleb; H Peng; P Harding; M Tayeh; M C LaPointe; O A Carretero
Journal:  Hypertension       Date:  2001-03       Impact factor: 10.190

2.  Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension.

Authors:  N E Rhaleb; H Peng; X P Yang; Y H Liu; D Mehta; E Ezan; O A Carretero
Journal:  Circulation       Date:  2001-06-26       Impact factor: 29.690

3.  N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo.

Authors:  Dahai Wang; Oscar A Carretero; Xiao-Yi Yang; Nour-Eddine Rhaleb; Yun-He Liu; Tang-Dong Liao; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-07-15       Impact factor: 4.733

4.  N-Acetyl-seryl-aspartyl-lysyl-proline inhibits ET-1-induced collagen production by preserving Src homology 2-containing protein tyrosine phosphatase-2 activity in cardiac fibroblasts.

Authors:  Hongmei Peng; Oscar A Carretero; Edward L Peterson; Xiao-Ping Yang; Kastuv Santra; Nour-Eddine Rhaleb
Journal:  Pflugers Arch       Date:  2012-09-12       Impact factor: 3.657

5.  Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline.

Authors:  K J Rieger; N Saez-Servent; M P Papet; J Wdzieczak-Bakala; J L Morgat; J Thierry; W Voelter; M Lenfant
Journal:  Biochem J       Date:  1993-12-01       Impact factor: 3.857

6.  Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline.

Authors:  M Azizi; A Rousseau; E Ezan; T T Guyene; S Michelet; J M Grognet; M Lenfant; P Corvol; J Ménard
Journal:  J Clin Invest       Date:  1996-02-01       Impact factor: 14.808

7.  Prolyl oligopeptidase is involved in release of the antifibrotic peptide Ac-SDKP.

Authors:  Maria A Cavasin; Nour-Eddine Rhaleb; Xiao-Ping Yang; Oscar A Carretero
Journal:  Hypertension       Date:  2004-03-22       Impact factor: 10.190

8.  Elevation of the antifibrotic peptide N-acetyl-seryl-aspartyl-lysyl-proline: a blood pressure-independent beneficial effect of angiotensin I-converting enzyme inhibitors.

Authors:  Megumi Kanasaki; Takako Nagai; Munehiro Kitada; Daisuke Koya; Keizo Kanasaki
Journal:  Fibrogenesis Tissue Repair       Date:  2011-11-30

Review 9.  N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes.

Authors:  Keizo Kanasaki; Takako Nagai; Kyoko Nitta; Munehiro Kitada; Daisuke Koya
Journal:  Front Pharmacol       Date:  2014-04-14       Impact factor: 5.810
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.